Stay updated with breaking news from James Mcbrayer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Key Insights Cyclopharm's significant retail investors ownership suggests that the key decisions are influenced by...
FDA approval for Cyclopharm's device-as-a-drug is welcome news, Tim Boreham reports
Key Insights Cyclopharm's significant retail investors ownership suggests that the key decisions are influenced by...
Why the Cyclopharm (ASX:CYC) share price is crashing 42% lower Some disappointing news from the FDA is sending investors running for the hills. Bernd Struben earned his economics degree in the US. Following several years writing about the tourism industry in the Caribbean, he moved to The Netherlands to cover the EU's booming commercial real estate markets. He moved to Australia in 2010, where he transitioned to analysing the Aussie equity markets. He employs a combination of macro economics and company specific data to gauge what he believes are tomorrow's best investments. In his free time,...
YARDLEY, PA / ACCESSWIRE / May 5, 2021 / Jubilant Radiopharma, a business division of Jubilant Pharma Limited, and Cyclomedica Europe Ltd, a wholly owned subsidiary of Cyclopharm Limited (ASX:CYC), will